🎗️ OncologyTablet (oral)
Zelboraf
VEMURAFENIB
Zelboraf is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with the BRAF V600E mutation, and for Erdheim-Chester disease with BRAF V600 mutation.
Form
Tablet (oral)
Uses
2
Side effects
4
Category
Oncology
01
What is Zelboraf used for?
- Treatment of unresectable or metastatic melanoma with BRAF V600E mutation
- Treatment of Erdheim-Chester disease with BRAF V600 mutation
02
VEMURAFENIB side effects
The following side effects have been reported for VEMURAFENIB. Their order does not indicate how often an effect occurs.
New primary cutaneous malignancies
Photosensitivity
Arthralgia
Fatigue
03
VEMURAFENIB warnings & precautions
- Risk of new primary cutaneous malignancies: perform dermatologic evaluations prior to and during treatment.
- QT prolongation has been observed. Monitor ECG before and during treatment.
Loading FDA data…
04
Frequently asked questions
05
Related medications
Share
Share this drug info.
Help friends and family understand Zelboraf in plain language.
Disclaimer: This information is sourced from the FDA openFDA database and is provided for educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before starting or changing medication.